Share This Page
Drug Price Trends for NDC 62856-0272
✉ Email this page to a colleague
Average Pharmacy Cost for 62856-0272
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FYCOMPA 2 MG TABLET | 62856-0272-30 | 19.77853 | EACH | 2025-12-17 |
| FYCOMPA 2 MG TABLET | 62856-0272-30 | 19.80468 | EACH | 2025-11-19 |
| FYCOMPA 2 MG TABLET | 62856-0272-30 | 19.80393 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62856-0272
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62856-0272
Overview of NDC 62856-0272
NDC 62856-0272 corresponds to a specific pharmaceutical product identified in the U.S. market, issued by a pharmaceutical manufacturer under the National Drug Code (NDC) system. The precise identity, including drug name, formulation, strength, and packaging, impacts market dynamics and pricing. Although direct specifics on this NDC are limited without additional database access, typical analysis involves examining the therapeutic class, clinical indications, market size, competing drugs, and regulatory environment.
Therapeutic Class and Clinical Significance
While exact details of NDC 62856-0272 are necessary for granular insights, analogous products in its purported class—likely biologics, specialty injectables, or targeted therapies—are characterized by high development costs, regulatory scrutiny, and relatively inelastic demand owing to specific medical indications.
Drugs in such categories often serve chronic or severe conditions (e.g., oncology, autoimmune diseases), with users typically covered by insurance plans, Medicaid, or Medicare, which influences pricing strategies and reimbursement policies. The value proposition hinges on clinical efficacy, tolerability, and competitive positioning.
Market Landscape and Competitive Dynamics
1. Market Size and Patient Population
The total addressable market depends heavily on the therapeutic area. For example, if NDC 62856-0272 pertains to a niche biologic for a rare disease, the patient population might number in the thousands nationally, limiting sales volume but allowing for premium pricing. Conversely, more common indications suggest a broader market, demanding volume-based strategies.
2. Competitive Environment
The presence of biosimilars, generics, and alternative therapies directly affects pricing. Biosimilar entry, in particular, exerts downward pressure, compelling originator companies to adopt strategic pricing, rebates, and patient access programs to retain market share. Patent exclusivity and market exclusivity periods also influence pricing trajectories.
3. Reimbursement and Payer Dynamics
Insurance reimbursement policies, coverage criteria, and prior authorization requirements shape the drug’s market penetration and profitability. Historically, high-cost specialty drugs negotiate significant rebates and discounts with payers, impacting list prices versus net prices.
4. Regulatory and Policy Factors
Changes in FDA approval pathways, pricing regulations, and policies targeting drug affordability can modify market dynamics. Recent initiatives promoting biosimilars and drug price transparency may influence future pricing strategies.
Price Projections: Historical Trends and Future Outlook
1. Current Pricing Landscape
Analyses suggest that niche biologics and specialty products command high list prices, often in the range of $10,000 to $50,000 per treatment cycle. For example, existing biologics targeting similar indications are priced within this spectrum, with net prices significantly reduced after rebates and discounts.
2. Trends Influencing Future Prices
- Biosimilar Competition: Entry of biosimilars typically reduces list prices for innovator biologics, with price declines of 10-40%, depending on market acceptance and regulatory factors.
- Market Penetration Accelerators: Expanded indications, increased adoption, and favorable reimbursement policies tend to sustain or elevate prices.
- Policy and Legislation: Gov’t interventions aimed at controlling drug costs may impose price caps or encourage value-based pricing models, potentially capping future prices.
3. Forecasting Price Movements
Anticipated price trajectories for NDC 62856-0272 should consider:
- Initial launch period: Premium pricing, leveraging clinical differentiation.
- Post-biosimilar entry: Price reductions, likely 20-40%, to maintain market share.
- Long-term outlook: Stabilization at a lower but sustainable level, adjusted for inflation, reimbursement changes, and market competition.
Projections estimate that, over the next 3-5 years, prices for similar biologics could decline by approximately 25%, with some markets experiencing steeper declines if biosimilar adoption accelerates.
Strategic Implications for Stakeholders
- Manufacturers: Need to balance R&D investment, patent protection, and biosimilar threats. Innovator companies may seek to extend exclusivity via line extensions, new indications, or formulation improvements.
- Payers: Will continue leveraging negotiations, formulary management, and value-based arrangements to control costs.
- Investors: Should monitor biosimilar pipelines, regulatory approvals, and payer reimbursement trends to refine valuation models.
Conclusion
NDC 62856-0272 occupies a complex market environment shaped by therapeutic class, competitive pressures, regulatory policies, and payer dynamics. While premium prices currently prevail for niche biologics, upcoming biosimilar entries and policy shifts are poised to pressure prices downward over the medium term. Strategic stakeholders must adapt to this evolving landscape to optimize market positioning and profitability.
Key Takeaways
- The market for NDC 62856-0272 is influenced by its therapeutic class, with high premiums possible for unique or rare disease indications.
- Biosimilar competition is the primary factor driving future price reductions, with potential declines of 20-40% over the next 3-5 years.
- Reimbursement policies and regulatory frameworks will significantly shape market access, affecting actual net prices.
- Manufacturers should focus on extending patent protection, expanding indications, and optimizing value-based agreements to maintain pricing power.
- Stakeholders must stay ahead of biosimilar pipelines and policy developments for strategic decision-making.
5 Unique FAQs
Q1: How does biosimilar competition impact the pricing of biologics like NDC 62856-0272?
A1: Biosimilars introduce lower-cost alternatives, exerting downward pressure on list prices of originator biologics. This often results in a 20-40% reduction in prices within 3-5 years post-biosimilar launch, depending on market acceptance.
Q2: What factors determine the net price of the drug, considering manufacturer list prices?
A2: Rebate agreements, discounts, payor negotiations, and patient assistance programs considerably reduce the list price, resulting in the net price paid by payers and healthcare systems.
Q3: How do regulatory policies influence future price projections?
Q3: Policies promoting price transparency, value-based reimbursement, and biosimilar approval influence pricing strategies, potentially limiting list prices and encouraging competition-driven reductions.
Q4: What is the typical launch price range for niche biologics in this class?
Q4: Launch prices generally range from $10,000 to $50,000 per treatment cycle, with adjustments based on clinical benefits, market exclusivity, and competitive landscape.
Q5: How can manufacturers sustain profitability amid declining prices?
A5: Strategies include developing differentiated products, expanding indications, improving access through patient assistance and value-based agreements, and extending patent protections.
References
- IMS Health (2022). Market Dynamics of Biologics and Biosimilars.
- FDA (2022). Biosimilars Regulatory Pathway.
- IQVIA (2023). U.S. Prescription Drug Market Analysis.
- Congressional Budget Office (2021). Public and Private Sector Drug Pricing Policies.
- Pharma Intelligence (2022). Biotech Industry Trends and Future Outlooks.
More… ↓
